Biohaven
biohaven.com
Health Care
Biologics & Biosimilars
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
FDA places partial clinical hold on Biohaven's epilepsy drug days after $795 million SK Biopharmaceuticals deal
Read more
Report
FDA places partial hold on Biohaven's epilepsy drug
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
Read more
Report
Report
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Read more
Report
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?
The Chief Accounting Officer added to his more than 85,000 shares held.
Read more
Report
Why BioHaven Stock Is Soaring Today
Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.
Read more
Report
Why Biohaven Stock Plummeted by More Than 15% Today
Why Biohaven Stock Plummeted by More Than 15% Today
Read more
Report
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven Ltd. (NYSE: BHVN) has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA). This rare and debilitating ne
Read more
Report